REPL stock news
This page provides real-time market news, earnings updates, and company announcements related to Replimune Group, Inc. (REPL).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-06-27 06:01 EST
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know
Finviz2026-02-12 15:57:40
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Finviz2026-03-10 16:34:27
JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
Finviz2026-03-10 16:37:38
The U.S. Food and Drug Administration (FDA) stated in a complete response letter regarding Replimune Group Inc. that the current clinical data is insufficient to demonstrate significant efficacy of its oncolytic virus therapy, vusolimogene oderparepvec.
老虎证券2026-04-10 15:44:59
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Finviz2026-04-10 21:06:48
Replimune's skin cancer drug is rejected again by the US FDA, causing the company's stock price to plummet
华尔街见闻2026-04-10 22:11:40
US Stock Movement | Replimune plunges over 56% in pre-market trading as RP1's listing application is rejected by the FDA again
格隆汇2026-04-13 08:48:56
The Nasdaq Biotechnology Index maintains a gain of over 1.1%, after previously rising more than 1.4%.
华尔街见闻2026-05-04 15:50:59
The Nasdaq Biotechnology Index closed up more than 2.1%. Among its constituents, Pyxis Oncology rose 25.68%, Veracyte gained 25.08%, MannKind (MNKD) increased 24.83%, Replimune was up 19.16%, and Novavax (NVAX) rose 15.56%.
华尔街见闻2026-05-06 22:00:02
Replimune Group Inc. has released the latest data on its candidate therapy Rp1 in combination with nivolumab, showing remarkable long-term survival benefits in patients with advanced melanoma who have developed resistance to PD-1 therapies, with a median overall survival of 32.9 months.
老虎证券2026-05-30 12:27:04
US Stock Movement | Replimune Rises Another 12% in Pre-market as Late-stage Melanoma Drug Application Sees Breakthrough
格隆汇2026-06-01 09:13:03
Replimune Group Inc. announced that the U.S. Food and Drug Administration (FDA) has officially accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1 for the treatment of advanced melanoma.
老虎证券2026-06-26 12:12:36
JPMorgan released its latest research report, significantly upgrading the stock rating of biotechnology company Replimune Group Inc. from "Neutral" to "Overweight."
老虎证券2026-06-26 15:45:13
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Finviz2026-04-10 21:06:48
Replimune's skin cancer drug is rejected again by the US FDA, causing the company's stock price to plummet
华尔街见闻2026-04-10 22:11:40
US Stock Movement | Replimune plunges over 56% in pre-market trading as RP1's listing application is rejected by the FDA again
格隆汇2026-04-13 08:48:56
The Nasdaq Biotechnology Index maintains a gain of over 1.1%, after previously rising more than 1.4%.
华尔街见闻2026-05-04 15:50:59
The Nasdaq Biotechnology Index closed up more than 2.1%. Among its constituents, Pyxis Oncology rose 25.68%, Veracyte gained 25.08%, MannKind (MNKD) increased 24.83%, Replimune was up 19.16%, and Novavax (NVAX) rose 15.56%.
华尔街见闻2026-05-06 22:00:02
Replimune Group Inc. has released the latest data on its candidate therapy Rp1 in combination with nivolumab, showing remarkable long-term survival benefits in patients with advanced melanoma who have developed resistance to PD-1 therapies, with a median overall survival of 32.9 months.
老虎证券2026-05-30 12:27:04
US Stock Movement | Replimune Rises Another 12% in Pre-market as Late-stage Melanoma Drug Application Sees Breakthrough
格隆汇2026-06-01 09:13:03
Replimune Group Inc. announced that the U.S. Food and Drug Administration (FDA) has officially accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1 for the treatment of advanced melanoma.
老虎证券2026-06-26 12:12:36
JPMorgan released its latest research report, significantly upgrading the stock rating of biotechnology company Replimune Group Inc. from "Neutral" to "Overweight."
老虎证券2026-06-26 15:45:13
REPL stock chart
REPL stock detailsREPL stock price change
On the last trading day, REPL stock closed at 10.64 USD, with a price change of -4.40% for the day.
Trade spot stocks (24/7)Trade stock perps (up to 100x leverage)About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
To provide deeper liquidity, a more transparent trading experience, and greater capital efficiency, Bitget officially launched its all-new spot stock product, Bitget Stocks 2.0, on June 2, 2026.
The new product is independently issued by licensed RWA protocol Reality, with Bitget providing strategic support and asset security safeguards. This marks a major upgrade to the stock trading experience.
Bitget is moving stock trading beyond the limits of traditional trading models by fully integrating stock assets into its margin and yield ecosystem.
Learn more